U.S. FDA approves Supernus' drug-device combination for Parkinson's disease
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
FiercePharma10d
Supernus' 4th try proves the charm with long-awaited FDA approval for Parkinson's infusion pump Onapgo
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
Supernus: New Approval Holds Promise Of Increased Growth
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
GlobalData on MSN8d
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
Stifel maintains hold on Supernus, price target at $38
Stifel analysts maintained their Hold rating on Supernus Pharmaceuticals (NASDAQ:SUPN) shares, with a steady price target of $38.00. Trading near its 52-week high with a strong 30% gain over the past ...
BioSpace9d
Supernus Taps Potential $300M US Opportunity With FDA Win for Parkinson’s Drug-Device Combo
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
Supernus stock price target raised to $44 at TD Cowen
Supernus Pharmaceuticals (NASDAQ:SUPN) stock received a price target increase from TD Cowen, with the target moving up to $44.00 from the previous $43.00. The firm maintained a Buy rating on the ...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...
MedCity News10d
Supernus Wearable Device for Dosing Parkinson’s Drug Lands Long-Awaited FDA Approval
A new Supernus Pharmaceuticals medical device that continuously administers an old Parkinson’s disease drug is now FDA approved, giving patients another way to manage the motor control symptoms ...
PMLiVE9d
FDA approves Supernus Pharmaceuticals’ Onapgo to treat advanced Parkinson’s disease
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection ...
Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight
According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...
Yahoo Finance9d
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...